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More recent researches have focused on metabolically healthy obese (MHO) phenotypes and on this phenotype,
individuals may be obese without metabolic disorders. Osteoarthritis (OA), kidney diseases and sleep disorders are
three factors related to the obesity that these conditions are associated only with obesity but not with metabolic
complications. Regardless of whether obese individuals are in metabolic groups or not, they should be treated. All
studies should be based on the risk of all-cause mortality in the MHO phenotypes.
Keywords: Obesity, Metabolic disorder, Osteoarthritis, Sleep disordersThe prevalence of obesity is increasing worldwide and
general and abdominal obesity are the major public health
and social problem [1]. The most important consequences
of obesity include type 2 diabetes, hypertension, hyperlip-
idemia, coronary heart diseases, ischemic stroke, certain
kinds of cancer, osteoarthritis, kidney diseases and sleep
disorders [1]. Some of these complications are related to
metabolic abnormality associated with obesity and others
are related to the obesity directly.
In some studies, association between weight status and
metabolic health has been proven but it is not applicable
for all subjects [2].
Osteoarthritis (OA), sleep disorders and kidney disease
are three complications related to the obesity that must
be considered apart from metabolic syndrome for obese
individuals. These three conditions are associated with
only obesity and over weight but not necessirily with
their metabolic complications.
It is established that obesity has been an independent
risk factor for osteoarthritis of the hip and knee [3]. It is
estimated that knee osteoarthritis will be doubled by* Correspondence: shirinhasanir@yahoo.com
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stated.2050 and through decreasing only 1% of BMI, the num-
ber of patients with knee osteoarthritis will be reduced
by 2050 [4].
And also sleep deprivation is associated with an in-
crease in body weight. Obstructive sleep apnea, insom-
nia and restless legs syndrome are three of the most
common sleep disorders. Several studies have shown
that there is a significant association between sleep dis-
orders and obesity [5].
Three phenotypes are known as “metabolically healthy
obese (MHO)”, “metabolically nonhealthy nonobese
(MNHNO)”, “metabolically nonhealthy obese (MNHO)”
[6]. In this classification BMI (Body Mass Index) is the
indication of definition.
More recent researches have focused on metabolically
healthy obese (MHO) phenotypes [7-9]. On this pheno-
type, individuals may be obese but metabolic disorders
do not exist (e.g. dyslipidemia, insulin resistance, hyper-
tension) [10]. A recent longitudinal study showed that
the MHO phenotype is associated with favorable cardio-
vascular outcomes, but this status is transient at one
third of the subjects [11]. Some studies have shown that
the subjects with MHO phenotype are not at increased
risk of morbidity and mortality and consequently treat-
ment of obesity for this group is unnecessary, but guide-
lines for treatment of obesity in the United States
suggest that regardless of cardiovascular diseases, obese
patients should be treated [12]. On the other handtd. This is an Open Access article distributed under the terms of the Creative
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with MHO phenotype, were not at increased risk of
cardiovascular diseases and mortality risk [13].
In summary, it is established that obese individuals
with metabolic problems are at higher risk of mortality
than their non-obese counterparts and should be treated
in order to decrease cardiovascular events. For metabol-
ically healthy obese individuals there is a gray zone. We
recommend that future studies consider the risk of all-
cause mortality and also morbidity (certain kinds of cancer,
osteoarthritis, kidney diseases and sleep disorders) in the
(MHO) phenotypes. This would open a new approach for
treatment of all obesity phenotypes.
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